Form 4: Amgen EVP Santos Exercises Options, Sells Shares

Amgen's EVP of Operations, Esteban Santos, exercised stock options and subsequently sold a portion of the acquired common stock to cover costs and taxes.

Summary

• Esteban Santos, Executive Vice President of Operations at Amgen Inc. (AMGN), reported transactions on February 26, 2026.
• Santos exercised Non-Qualified Stock Options (NQSOs) for a total of 54,792 shares of common stock.
• Specifically, 30,501 shares were acquired at an exercise price of $162.60 per share, and 24,291 shares were acquired at an exercise price of $177.46 per share.
• Concurrently, Santos sold 54,792 shares of Amgen common stock at an average price of $379.1173 per share.
• These sales were primarily conducted to cover the option exercise price and required withholding taxes in connection with the exercise of expiring options.
• Following these transactions, Santos directly beneficially owns 76,618 shares of common stock.
• Santos also indirectly owns 903.8036 shares through the Company's 401(k) Plan and 624 Dividend Equivalents (DEs) credited to unvested Restricted Stock Units (RSUs).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a slightly positive, routine insider transaction. The executive is monetizing vested options, which is a normal part of compensation, and the sale is primarily for tax and exercise cost coverage, not a signal of lack of confidence.

Positives

• The executive exercised a significant number of stock options, indicating that the options had substantial in-the-money value, reflecting past stock price appreciation.
• The sale price of $379.1173 per share is significantly higher than the exercise prices of $162.60 and $177.46, demonstrating a substantial gain for the executive from their equity compensation.

Negatives

• The sale of shares, even if for tax purposes, reduces the executive's direct ownership stake in the company.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that routine insider transactions, such as option exercises followed by sales to cover taxes and exercise costs, are common across the pharmaceutical and biotechnology industries. These transactions typically do not signal a significant shift in company outlook or executive sentiment, unlike large, unprompted open-market sales.

Comparison to Industry Standards

• StockSavvy.ai observes that the executive's decision to exercise options with strike prices significantly below the current market price is a standard practice for maximizing compensation from equity awards. This is consistent with executive compensation structures seen at peer companies like Pfizer (PFE) or Johnson & Johnson (JNJ), where executives frequently monetize vested options as part of their long-term incentive plans.
• The sale of shares to cover the option exercise price and required withholding taxes is also a common and expected component of such transactions, aligning with practices observed across major publicly traded companies.

Stakeholder Impact

• Shareholders: The transaction is a routine insider filing and does not typically indicate a significant change in company fundamentals or executive sentiment that would materially impact shareholders.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the exercise of stock options and a subsequent sale of shares to cover taxes and exercise costs. Such transactions are common and generally do not provide a strong signal for a 'buy' or 'sell' recommendation. The executive is monetizing vested compensation, which is expected. Therefore, a 'hold' recommendation is appropriate as this event does not fundamentally alter the investment thesis for Amgen.

Keywords

Amgen, AMGN, insider trading, stock options, executive compensation, Form 4, biotechnology, pharmaceuticals